title: Targeting backup DNA repair in cancer.
abstract: New research shows that DNA polymerase θ is a key player in PARP-mediated DNA damage repair and essential for the survival of cancer cells where homologous recombination is compromised. Polθ could be a biomarker for PARP-inhibitor response, and is a potential therapeutic target for overcoming resistance to these drugs.
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D004260:DNA Repair; D017277:Drug Approval; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy* / Q000235:genetics*; D000067856:Poly(ADP-ribose) Polymerase Inhibitors / Q000627:therapeutic use*; D014481:United States; D014486:United States Food and Drug Administration
chemical_list: D000970:Antineoplastic Agents; D000067856:Poly(ADP-ribose) Polymerase Inhibitors